Faculty: Kae Jack Tay, MD, Peter Pinto, MD and Leonard Marks, MD

Moderator: Ardeshir Rastinehad, MD

Kae Jack Tay, MD

Dr. Tay is a Director of Urologic Oncology and Consultant Urologist at the Singapore General Hospital. He completed his urology residency at the Singapore General Hospital and his fellowship at Duke University, North Carolina, USA. Dr. Tay’s clinical practice includes focal therapy for prostate cancer, robotic pelvic surgery, complex resections of genitourinary (GU) cancers in the pelvis and retroperitoneum, and metastatic prostate cancer. He is an Adjunct Assistant Professor at the Duke-NUS Graduate Medical School and is the Principal Investigator for a Phase II trial of Focal Cryotherapy for Prostate Cancer. He currently holds a National Medical Research Council grant for prostate cancer risk stratification, advanced imaging, biopsy, active surveillance, cryotherapy and focal therapy.

Dr. Tay has written more than 70 publications on the topic of urologic cancer. He collaborates on several international multicenter projects including the Cryo On-Line Data (COLD) registry and the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Dr. Tay has participated in several international expert consensuses on prostate focal therapy including the International Consultation of Urological Diseases (ICUD) consensus on follow-up surveillance after prostate focal therapy and an international consensus on Patient Selection for Prostate Focal Therapy.

Dr. Tay is also a Board Member for the Focal Therapy Society and is presently the chairman of its Website and Social Media Committee. He aims to develop better risk stratification methods for localized and metastatic prostate cancer and a modern approach to precision medicine in prostate cancer.

Peter Pinto, MD

Peter A. Pinto, M.D. is a Principal Investigator, Head of the Prostate Cancer Section and Fellowship Director in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Maryland. After completing his residency in Urologic Surgery at Long Island Jewish Medical Center, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins.

Dr. Pinto has a robust clinical practice in the management of localized and locally advanced prostate cancer. His translational research interests include vaccine strategies and molecularly-targeted therapeutic approaches to modulate cancer cell growth and survival, device development and artificial intelligence for imaging and targeted registration of genitourinary tumors to improve diagnosis and treatment, and the minimally invasive treatment of urologic malignancies, including laparoscopic/robotic surgery and focal therapy such as laser ablation, cryotherapy, radiofrequency ablation, and high intensity focused ultrasound. He is nationally and internationally recognized as an expert in the field of prostate cancer and image guidance to improve active surveillance, focal therapy and robotic surgery. He holds multiple patents in the novel method and system of performing image guided biopsies and was the co-creator of the UroNav MRI-Ultrasound fusion prostate biopsy platform.

Leonard Marks, MD

David Geffen School of Medicine at UCLA
Los Angeles, California

Leonard S. Marks, MD, is Professor and inaugural holder of the deKernion Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles. He graduated from the University of Texas Medical Branch, where he received his MD with AOA honors and his MA in Physiology in 1969. He served an internship and surgical residency at UCLA/Harbor General Hospital. For the following two years, he served on active duty as Lieutenant Commander in the US Public Health Service. He was named a Post-Doctoral Research Scholar at UCLA School of Medicine in 1973-4. He completed his Urology Residency at UCLA and was a Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles. He re-joined the UCLA faculty full-time in 2009. While in practice, Dr. Marks founded a non-profit research organization, the Urological Sciences Research Foundation, a 501c3 corporation, to further his academic interests. He became an original AFUD scholar in 1992 for work relating serum PSA levels to prostate histology. He received a Prostate Cancer Foundation (PCF) research award in 2000 for cross-cultural studies of prostate cancer. As an early advocate of multimedia in medical education, he served as Website Editor of Urology for The Gold Journal from 1998-2010. For his work in the scientific evaluation of alternative medicines, he was appointed to committees of the American Urological Association, the National Institutes of Health, and the National Academy of Sciences. Over the past decade, he has been Principle Investigator of three separate R01 Awards from the National Cancer Institute devoted to targeted prostate biopsy and focal therapy of prostate cancer. He has authored more than 150 scientific publications.

Ardeshir Rastinehad, MD

Ardeshir (Art) R. Rastinehad D.O.
Northwell Health’s System Director for Prostate Cancer
Vice Chair at the Smith Institute for Urology at Lenox Hill

Dr. Art Rastinehad, D.O. initially joined the faculty at Northwell Health in 2011. Most recently, he was named Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair at the Smith Institute for Urology at Lenox Hill Hospital (January 2020). He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery. These hybrid skills were developed under the patience and kindness of his mentors Gopal Badlani (uro), Peter Choyke (rad), Louis Kavoussi (uro), Marston Linehan (uro), Igor Lobko (rad), Peter Pinto (uro), David N. Siegel (rad), Arthur Smith (uro), and Bradford Wood (rad).

Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship as a teaching fellow in anatomy for his last three years of medical school. During this time Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach, subsequently completing a urology residency and interventional radiology fellowship at North Shore LIJ in 2009. Soon after, Dr. Rastinehad trained at the National Cancer Institute (2009-2011) as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology.

Dr. Rastinehad has also authored and implemented several clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principal investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques and validated the original work from the NIH’s UOB/MIP/CIO programs. This was the first trial of this technology in the United States outside the National Institutes of Health. Dr. Rastinehad is considered one of the pioneers of this field, bringing prostate MRI and MR/US fusion guided prostate biopsy from the bench to clinical practice.

This new clinical approach is the groundwork for the evaluation of a new technique, Focal Therapy, which treats only the diseased portion of the prostate. While at the NIH, Dr. Rastinehad designed and authored the first trial assessing the utility of MR guided focal ablation of prostate tumors using MR US fusion biopsy data with Dr. Pinto as the PI (2010). As of May 2016, Dr Rastinehad was the first in the world to perform a gold nanoparticle directed ablation using a transperineal MR/US Fusion guided focal therapy system. This was the first-time nanoparticles were utilized to focally treat any cancer and this first series was recently published in Proceedings of the National Academy of Science (PNAS).

Dr Rastinehad is also one of the founding executive board members of the Focal Therapy Society (along with Drs. Polascik, De La Rosette, and Sanchez-Salas), which was started in October 2019 in collaboration with the Endourological Society. The society continues to grow and establish solid scientific principles to critically evaluate, disseminate, and perform focal therapy. In addition to his leadership role within the Focal Therapy Society, Dr. Rastinehad has been the course director and/or faculty for more than 30 courses nationally and internationally at the AUA, Endourological Society, Focal Therapy Society, and Société Internationale d'Urologie. Along with Dr. Pinto, he was the course director on the first use of MR/US fusion guided prostate biopsies in 2014. Continuing his goal to help bring these new treatments and approaches to the urologic community, he is currently developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety. These efforts will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms.

Dr. Rastinehad’s research has been published in leading national and international medical journals. He has published over 200 articles, videos, and multiple textbook chapters and was the senior editor of the first comprehensive textbook on the subject, ‘Interventional Urology’, in 2016. Dr. Rastinehad continues to dedicate his time to caring for patients by researching and developing new diagnostic and therapeutic interventions for urologic diseases, as well as training the next generation of urologists. He has formalized the training required for learning the skills of interventional urology (IU) with the establishment of the first and only IU program in the world.